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Colorectal cancer (CRC) is the third most common diagnosed cancer worldwide, but
there are no effective cures for it. Hyaluronan and proteoglycan link protein-1 (HAPLN1) is
a component of the extracellular matrix (ECM) proteins and involved in the tumor
environment in the colon. Transforming growth factor (TGF)-b is a key cytokine that
regulates the deposition of ECM proteins in CRC. However, the role of HAPLN1 in TGF-b
contributions to CRC remains unknown. We found that the mRNA expression of HAPLN1
was decreased in tumors from CRC patients compared with healthy controls and normal
tissue adjacent to the tumor using two existing microarray datasets. This was validated at
the protein level by tissue array from CRC patients (n = 59). HAPLN1 protein levels were
also reduced in human CRC epithelial cells after 24 h of TGF-b stimulation, and its protein
expression correlated with type I collagen alpha-1 (COL1A1) in CRC. Transfection of
HAPLN1 overexpression plasmids into these cells increased protein levels but reduced
COL1A1 protein, tumor growth, and cancer cell migration. TGF-b stimulation increased
Smad2/3, p-Smad2/3, Smad4, and E-adhesion proteins; however, HAPLN1
overexpression restored these proteins to baseline levels in CRC epithelial cells after
TGF-b stimulation. These findings suggest that HAPLN1 regulates the TGF-b signaling
pathway to control collagen deposition via the TGF-b signaling pathway and mediates E-
adhesion to control tumor growth. Thus, treatments that increase HAPLN1 levels may be
a novel therapeutic option for CRC.
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Colorectal cancer (CRC) is the third most commonly diagnosed
cancer worldwide and the second most lethal with more than
900,000 deaths annually (1). The number of new cases is
predicted to reach 2.5 million in 2035 (1). With early
diagnosis, the 5-year survival rate of CRC is ~65%, but this
drops to less than 10% at later stages (2). The cause of tumor
formation in CRC remains unknown. Polyps induce long-term
inflammation in the colon and may contribute to tumor
development of CRC (3). Tissue microenvironment changes
also result in tumor formation in CRC. Therefore, it is
important to understand the processes that lead to the
development and growth of tumors in CRC.
Extracellular matrix (ECM) proteins are a group of
macromolecules that provide structural support to cells.
Alterations in ECM protein deposition result in aberrant
structural changes in tissues, and ECM protein levels need to
be balanced to maintain a normal microenvironment in the
colon. Hyaluronan and proteoglycan link protein-1 (HAPLN1) is
an ECM component that stabilizes other ECM proteins (4).
Studies show that a loss of HAPLN1 proteins promotes
metastasis of melanoma in patients, and tumor growth is
inhibited by reconstitution of HAPLN1 (5). Also, HAPLN1 has
important roles in maintaining endothelial permeability, and its
loss promotes metastasis via blood vessels (6). However, the role
of HAPLN1 in CRC has not been widely studied and
remains unclear.
Transforming growth factor (TGF)-b is an important
cytokine that has major beneficial functions in wound repair,
but is also involved in tumor cell survival, invasion, and
metastasis in many cancers, including CRC (7). Indeed,
previous studies show that increased TGF-b promotes tumor
cell proliferation in CRC patients (8, 9). TGF-b is also a central
factor in regulating ECM genes and proteins in many diseases
(10). Previous studies showed that TGF-b challenge reduced
HAPLN1mRNA expression in human brain cells after 24 h (11).
Another study found amplified HAPLN1 mRNA levels in CRC
patients (n = 15) (12), but protein levels have not been assessed in
CRC. Links between TGF-b signaling and HAPLN1 in CRC
remain unknown.
We hypothesized that HAPLN1 is a key ECM protein that
regulates tumor growth and development in CRC. In this study,
HAPLN1 mRNA and protein levels were measured in tumor,
normal tissue adjacent to tumors, and healthy control tissue in
existing microarray datasets and protein tissue arrays. TGF-b
challenge reduced HAPLN1 protein levels in human CRC
epithelial cells. We also found that decreased HAPLN1
negatively correlated with collagen expression and contributes
to tumor development in CRC.HAPLN1 overexpression restored
protein levels in human CRC cells after TGF-b challenge and
reduced collagen and tumor cell growth in CRC. Thus, we
propose that TGF-b signaling reduces HAPLN1 levels that
leads to collagen production and CRC. These data highlight
the role of HAPLN1 as an important suppressor of tumor growth
in CRC.Frontiers in Oncology | www.frontiersin.org 2MATERIALS AND METHODS
Gene Expression in Human CRC
Microarray Datasets
HAPLN1 gene expression in colorectal tumor and normal tissue
adjacent to tumors from CRC patients and healthy controls was
assessed in two existing microarray datasets (GSE128449 and
GSE110224) in the Gene Expression Omnibus (GEO). Normal
tissues adjacent to tumors were described to be those normal
samples dissected from adjacent tumors (>4 cm from the tumor)
from the same CRC patients (13). The data were analyzed using
Bioconductor in R as previously described (14–16).
In the GSE128449 dataset, gene microarray from colorectal
tissues was obtained from healthy controls (n = 5) and CRC
patients (n = 31). Data were profiled by Agilent-014850 Whole
Human Genome Microarray 4x44K G4112F. In the GSE110224
dataset, gene microarray from colorectal tissues and normal
tissues adjacent to tumors was obtained from 17 CRC patients
of similar age during surgery (17). mRNAs were profiled by
Affymetrix Human Genome U133 Plus 2.0 array. The
Benjamini–Hochberg method for adjusted P-value/false
discovery rate (FDR) was used to analyze differences between
groups. Statistical significance was set at FDR <0.05. All target
gene expression was calculated as log2 intensity robust multi-
array average signals (log2-transformed intensity value) (18).
Human Subjects
Human colon cancer tumor (CD4, SuperBioChips Laboratories,
Seoul, South Korea) and normal tissues adjacent to tumor
samples (CDN4, SuperBioChips Laboratories, Seoul, South
Korea) were obtained from 59 stage I–IV CRC patients in
tissue array slides (Table 1). The tumor and normal tissues
adjacent to tumor tissues were collected during colorectal surgery
and fixed with formalin. The tissues were dehydrated with
gradient ethanol (70%, 90%, 95%, 99%, and 100%) for 1 h for
each progressive step and paraffin embedded at 60°C for 3 h. The
tissue blocks were sectioned in 4 mm thickness on new silane III
slides (Cat # 5116-20F, Muto Pure Chemicals).
Survival Analysis
CRC samples with HAPLN1 low (n = 176) and high (n = 242)
gene expression were obtained from the colons of CRC patients
(stages I–IV, Supplementary Table S1) based on The Cancer
Genome Atlas Program (TCGA, https://ww.cancer.gov/tcga)
(19). The Kaplan–Meier survival curve was produced using R
packages survival and survminer by OncoLnc (http://www.
oncolnc.org) (20). The relationship between HAPLN1 gene
expression and overall patient survival time was verified using
a log-rank test.
Single-Cell Analysis of Human
CRC Dataset
HAPLN1 gene expression from different cell clusters in CRC was
assessed in previously published single-cell RNA-sequencing
dataset (21). Single cells were obtained from tumor tissues
that were resected from CRC patients (n = 31) as previouslyDecember 2021 | Volume 11 | Article 754240
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Chromium system (10x Genomics) across eight lanes on a
HiSeq 4000 platform. Cells were clustered and visualized using
t-distributed stochastic neighbor embedding (tSNE) plots as
previously described (16, 21). The cellular sources of HAPLN1
mRNA in CRC were identified using the UCSC cell browser.
Immunohistochemistry
Slides of human colon cancer and normal tissues adjacent to
tumor tissue were incubated at 60°C for 30 min, deparaffinized
with xylene (5 min twice), and dehydrated in 100%, 95%, 90%,
and 75% ethanol for 2 min (twice each). They were then
incubated in citrate buffer (pH 6.0) at 100°C (35 min) for
antigen retrieval and blocked with 5% bovine serum albumin
(A9418, Sigma-Aldrich) at room temperature for 1 h. Slides were
then incubated with HAPLN1 (1:100, sc-46826, Santa Cruz
Biotechnology), p-Smad2/3 (1:100, SAB454208, Merck), and
type I collagen alpha-1 (COL1A1, 1:100, ab21286, Abcam)
antibodies at 4°C overnight, and then with anti-rabbit
horseradish peroxidase-conjugated secondary antibody
(HAF008, R&D Systems, USA) at room temperature for 1 h.
They were washed in PBS-Tween 20 (three times, 5 min)
with shaking, and sections were incubated with 3,3′-
diaminobenzidine (DAB) chromogen solution at room
temperature for 10 min according to the instruction of the
manufacturer (GV825, Agilent). Slides were counterstained
with hematoxylin at room temperature for 5 min. Images were
taken under ×5 and ×20 magnifications using a light microscope.
The area of HAPLN1 proteins was calculated using ImageJ with a
color deconvolution plug-in (ImageJ) as previously described
(22). The percentage of HAPLN1 protein in each image (at least
20 random images) was calculated by the area of positive staining
divided by the total area of the view under ×20 magnification.
Cell Culture
Human CRC epithelial cells (Caco-2, HTB-37, ATCC, Manassas,
VA, USA) were maintained in Eagle’s minimum essential
medium (EMEM) containing 2.5 mM L-glutamine, 10 mM
HEPES, and 10% fetal bovine serum (FBS) at 37°C with 5%
CO2. Cells (1 × 10
5 cells/well) were seeded in a six-well plate and
cultured in EMEM medium with 0.1% FBS at 37°C with 5% CO2
for 24 h. Human recombinant TGF-b protein (50 mg/ml, 7666-
MB-005/CF, R&D Systems) was added to the cell media, and
control cells received an equal volume of EMEM medium. CellFrontiers in Oncology | www.frontiersin.org 3lysates were collected after 6, 12, 24, and 48 h for immunoblot.
Some cells were seeded on coverslips in a 24-well plate overnight
and treated with TGF-b recombinant protein for 6, 12, 24, and
48 h, and cells were collected for immunofluorescence assays.
Protein Extraction
Cell lysates were obtained using radioimmunoprecipitation assay
buffer (RIPA; Sigma-Aldrich, St. Louis, USA) supplemented with
protease and phosphatase inhibitors (Thermo Fisher Scientific,
MA, USA). Lysed cell samples were centrifuged (8,000×g,
10 min, 4°C) and supernatants were collected for protein
assays. Total protein concentrations in cell lysates were
determined using a Pierce bicinchoninic acid (BCA) protein
assay kit (Thermo Fisher Scientific, MA, USA) according to the
instructions of the manufacturer.
Immunoblot
Proteins from cell lysates were separated by electrophoresis
under 110 V for 1.5 h and transferred onto polyvinylidene
difluoride (PVDF) membranes. Membranes were blocked with
5% BSA for 2 h at room temperature, and then incubated with
anti-HAPLN1 (1:100, sc-46826, Santa Cruz Biotechnology),
COL1A1 (1:2,000, ab21286, Abcam), E-cadherin (1:2,000,
3195S, Cell Signaling), Smad2/3 (1:2,000, 8685S, Cell
Signaling), Smad4 (1:2,000, 46535S, Cell Signaling), p-Smad2/3
(1:1,000, SAB454208, Merck), and anti-b-actin (1:10,000,
ab8226, Abcam, Cambridge, UK) antibodies at 4°C overnight.
Blots were washed with TBS-Tween 20 (three times, 10 min) and
incubated with anti-rabbit or anti-mouse IgG HRP-conjugated
antibodies (R&D Systems, MN, USA) at room temperature for
2 h. Substrate (SuperSignal™ West Femto Maximum Sensitivity
Substrate, Thermo Fisher Scientific, MA, USA) was added to the
membrane and images of immunoblots were captured using a
ChemiDoc MP System (Bio-Rad, Hercules, USA). Some blots
were stripped (15 g glycine, 1 g SDS, 10 ml Tween 20, pH 2.2) but
only once to avoid background effects. Densitometry analysis
was performed relative to the housekeeping protein b-actin using
ImageJ (NIH, Bethesda, USA) as previously described (23, 24).
The fold change of normalized area in each challenge/treatment
group was compared with the control group.
Immunofluorescence
Caco-2 cells were fixed with cold methanol (−20°C) and 3%
paraformaldehyde in PBS (pH 7.4) both at room temperature for
10 min each, permeabilized with 0.2% Triton X-100, and blocked
with 5% BSA at room temperature for 1 h. Cells were incubated
with anti-human HAPLN1 (1:100, sc-46826, Santa Cruz
Biotechnology), COL1A1 (1:100, ab21286, Abcam), or p-
Smad2/3 (1:100, SAB454208, Merck) antibodies at 4°C
overnight. After three washes with PBS-Tween 20, cells were
incubated with FITC-conjugated anti-rabbit secondary antibody
(1:100, ab6717, Abcam) or AF594 anti-rabbit secondary
antibody (1:200, ab150080, Abcam) at room temperature for
1 h. Nuclei were counterstained with DAPI at room temperature
for 5 min. Ten random images per section were visualized using
an Axio Imager M2 microscope and analyzed using an imagingTABLE 1 | Patient characteristics (n = 59).
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percentage of HAPLN1-positive cells was calculated as the
percentage of the total cell number (DAPI-positive cells).
HAPLN1 Overexpression Treatment
HAPLN1 overexpression plasmids within a pCMV3-C-GFPSpark®
vector (HG10323-ACG, Sino Biological, China) or negative control
(CV026, Sino Biological, China) plasmids (200 pg/ml) were
transformed into SIG10 chemically competent cells (CMC0001,
Sigma-Aldrich) according to the instructions of the manufacturer.
Cells were cultured in LB broth at 37°C for 3 h with 200 rpm
shaking. Cells were then cultured on LB agar plates (L3147, Sigma‐
Aldrich, St. Louis, USA) containing kanamycin sulfate (200 mg/ml,
60615, Sigma‐Aldrich, St. Louis, USA) at 37°C overnight. A single
colony was collected and cultured in LB broth at 37°C for 6 h with
200 rpm shaking, and bacterial cells were collected by centrifugation
(6,000 rpm at room temperature for 10min). Plasmids were isolated
and purified using a PureLink HiPure Plasmid Midiprep kit
(Thermo Fisher Scientific, Waltham, USA) according to the
instructions of the manufacturer (25). Caco-2 cells (2 × 105 cells/
well) were seeded in EMEM media (0.1% BSA and without
antibiotics) on a 24-well plate at 37°C overnight. HAPLN1 or
negative control plasmids (1,000 ng) were transfected into Caco-2
cells using Lipofectamine 3000 transfection reagent (L3000008,
Thermo Fisher Scientific, Waltham, USA) according to the
instructions of the manufacturer. Cell lysates were collected after
12, 24, and 48 h for immunoblot analysis. Some cells were seeded on
coverslips for immunofluorescence assays.
Cell Proliferation Assay
To investigate cell proliferation, Caco-2 cells (1 × 104 cells/well)
were seeded in a 96-well plate and then transfected with
HAPLN1 overexpression or negative control plasmids. Cells
were incubated with TGF-b recombinant protein (50 mg/ml)
for 24 h and control cells received media only. Cells were stained
with crystal violet (10%) at room temperature for 20 min and
incubated with methanol at room temperature for 10 min. At
least 10 random images were taken using a light microscope
under ×40 magnification. Crystal violet-positive cells were
enumerated using ImageJ as previously described (26).
Wound Healing Assay
Caco-2 cells were cultured on a 24-well plate with serum-free
media for 24 h. The cells were scratched with a p200 pipette tip to
generate a straight line across the center of each well as
previously described (26), and then gently washed three times
with PBS. Fresh serum-free EMEM media with TGF-b
recombinant protein (50 mg/ml) were added to each well and
control cells received media only. Cells were incubated at 37°C
for 24 h with 5% CO2. Images were taken using a phase-contrast
microscope at 0, 6, 12, and 24 h after scratching. The area of each
scratch at each time point was compared to images from 0 h
using ImageJ software.
Cell Migration Assay
CRC cell migration was assessed using Boyden’s chamber assay
as previously described (27). Caco-2 cells (2 × 104 cells/ml) wereFrontiers in Oncology | www.frontiersin.org 4seeded in upper chambers (Transwell) with 200 ml of DMEM
media (1% FBS). Chambers were cultured in wells of 24-well
plates containing 750 ml of DMEM overnight. Some cells were
transfected with HAPLN1 overexpression or negative control
plasmids for 24 h using Lipofectamine 3000. Controls received
equal volumes of media. Cells were then incubated with
recombinant TGF-b protein for 24 h. Non-migrated cells
remaining on the top surface of Transwell membrane were
removed using cotton swabs. Cells that migrated to the lower
surface of the membranes were fixed with 10% formalin (15 min)
and permeabilized with methanol (5 min). Cells were then
stained with crystal violet. Migrated cells were visualized and
counted in at least five random fields per well under ×20
magnification using an inverted microscope.
Tissue Atlas Protein Analysis
Representative immunohistochemistry images of Smad2, Smad3,
Smad4, and COL1A1 proteins in human healthy control colon
and tumors from CRC patients were obtained from the Human
Atlas database (version 19.3) as previously described (16).
Statistical Analysis
Results are presented as mean ± standard error of the mean (SEM).
Each in-vitro experiment was performed in triplicate and repeated
in three to four independent experiments. Unpaired Student’s t-tests
were used to compare two groups, and one-way analysis of variance
(ANOVA) with Bonferroni comparisons was used to compare the
results of more than two groups. All statistical analyses were
performed using GraphPad Prism Software (San Diego, CA,
USA). Statistical differences were accepted at P <0.05.RESULTS
HAPLN1 Gene Is Decreased in
CRC Patients
Previous studies showed that HAPLN1 was involved in tissue
remodeling (6), but its role in CRC remains unknown. We
assessed the HAPLN1 mRNA levels in CRC patients and
colons from healthy controls using an existing microarray
dataset (GSE128449). We found that HAPLN1 mRNA was
significantly decreased in CRC patients compared with healthy
tissues (Figure 1A). To further assess the level of HAPLN1 in
CRC patients, we measured HAPLN1 mRNA in tumor tissues
and their normal tissues adjacent to the tumor in CRC patients
using another microarray dataset (GSE110224).HAPLN1mRNA
levels were also decreased in tumor compared with normal
tissues adjacent to tumor tissues in the same CRC patients
(Figure 1B). We also found that low expression of the
HAPLN1 gene in CRC patients correlated with shorter survival
periods than those with high HAPLN1 expression (P = 0.035,
Figure 1C). To define the cellular source of HAPLN1 in CRC,
tumors were collected from 31 CRC patients (21) and single-cell
RNA-sequencing analysis was preformed (Figure 1D). HAPLN1
mRNA was found in epithelial, stromal, and endothelial cells and
myofibroblasts (Figure 1E).December 2021 | Volume 11 | Article 754240
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CRC Patients
To confirm that the decrease of HAPLN1 mRNA translates to
reduced protein levels in CRC patients, we assessed the HAPLN1
protein in tumor and normal tissues adjacent to tumor tissues from
59 CRC patients using immunohistochemistry (Figure 2A), and the
HAPLN1 protein was mainly produced by CRC epithelial cells. The
HAPLN1 protein was decreased in tumor (stage I–IV cancer)
compared with normal tissues adjacent to tumor tissues
(mean = 35.56 vs. 22.73, Figure 2B). The level of HAPLN1
protein was further reduced in severe stage (III–IV) CRC
compared with early stages (mean 13.48 vs. 10.5, Figure 2C).
TGF-b Reduces HAPLN1 Proteins in
Cancer Cells
Many studies have shown that CRC is associated with increased
TGF-b protein and its downstream signaling is the key driver ofFrontiers in Oncology | www.frontiersin.org 5tumor development (28). Previous studies also showed that TGF-b-
induced ECM proteins led to the changes in the tissue
microenvironment and tumor formation (26). COL1A1 is the
most abundant ECM proteins in human (10). We examined the
presence of abnormal ECM deposition and microenvironment
change in CRC using TGF-b challenge of human CRC epithelial
cells and assessing the levels of COL1A1 proteins over a time course
(6, 12, 24, and 48 h, Figure 3A and Supplementary Figure S1A).
TGF-b challenge resulted in significantly increased COL1A1 protein
in the cell lysates reaching a peak after 24 h (Figure 3B).
To assess the role of HAPLN1 in CRC, we then measured its
protein levels in cell lysates by immunoblot (Figure 3A). TGF-b
challenge reduced HAPLN1 proteins in CRC epithelial cells from
the 6-h time point with the maximal decrease after 24 h
compared with controls (Figure 3C).
To further assess HAPLN1 in CRC, we challenged human




FIGURE 1 | HAPLN1 gene expression is decreased in colorectal cancer (CRC) patients. (A) HAPLN1 gene expression was analyzed in colon tissues from healthy
(n = 5) and CRC patients (n = 31) in the GSE128449 dataset. (B) HAPLN1 gene expression was analyzed in colon tissues from tumor and normal tissue adjacent to
the tumor from the same CRC patients (n = 17) in the GSE110224 dataset. (C) The Kaplan–Meier survival curve of the correlations between the mRNA expression of
the HAPLN1 gene and survival days, and the cutoff value of RNA expression was 27.8. (D) Single cells were isolated from tumors in CRC patients (n = 31) after
surgery. Cells were clustered using a graph-based shared nearest neighbor clustering approach and visualized in a t-distributed stochastic neighbor embedding
(tSNE) plot in UCSC cell browser. (E) mRNA expression of HAPLN1 in different cells in CRC patients. Results are mean ± SEM. **P < 0.01, ***P < 0.001 compared
with healthy control or non-tumor adjacent tissues.December 2021 | Volume 11 | Article 754240
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p-Smad2/3 (active version of Smad2/3) is an important
downstream mediator in the TGF-b signaling pathway.
p-Smad2/3-positive cells increased after 6 h of TGF-b
compared with controls, were then maintained at the same
level up to 24 h, but then decreased at further time points
(48 h, Figure 3E). TGF-b reduced the percentage of HAPLN1-
positive cells, with the greatest effect after 24 h (Figure 3F), and
this confirmed our result in cell lysates.
Overexpression of HAPLN1 Gene in CRC
Epithelial Cells Reduces Tumor Growth
Given that CRC development was associated with a decrease in
HAPLN1 protein levels, to further understand its role, we
transfected HAPLN1 overexpression or negative control plasmid
into human CRC epithelial cells. We assessed HAPLN1
overexpression plasmid transfection efficiency by enumerating
GFP-positive cells at different time points (6, 12, 24, and 48 h)
after plasmid transfection as the plasmid contained the GFP
gene (Figure 4A). The number of GFP-positive cells peaked
24 h after transection (Figure 4B) with a decrease after 48 h.
We also measured HAPLN1 proteins in cell lysates during
the transfection time course by immunoblot (Figure 4C
and Supplementary Figure S1B). HAPLN1 proteins were
significantly increased 24 h after transfection, but the levels
decreased thereafter (Figure 4D), which confirmed the
immunofluorescence data (Figure 4A). Therefore, we chose
24 h as the optimized transfection time point.Frontiers in Oncology | www.frontiersin.org 6We also found that COL1A1 proteins were decreased in CRC
epithelial cells after HAPLN1 overexpression plasmid transfection
(Figure 4E). COL1A1 proteins were the lowest after 24 h
corresponding with the highest level of HAPLN1 proteins,
indicating a correlation between HAPLN1 and COL1A1 proteins.
HAPLN1 Changes the Tumor
Microenvironment by Regulating Collagen
Production in CRC
To better understand the role of HAPLN1 in regulating CRC
growth, we transfected HAPLN1 overexpression plasmid with and
without TGF-b recombinant protein and examined the effects after
24 h. Human CRC epithelial cell growth significantly increased with
concomitant TGF-b protein challenge, with an ~3-fold increase of
cells after 24 h compared with controls (Figure 5A). HAPLN1
overexpression reduced CRC growth compared with cells
transfected with the negative control plasmid and media controls
with concomitant TGF-b (Figures 5A–C). We further assessed the
role of HAPLN1 in CRC using migration assays (Figure 5D). TGF-
b recombinant protein significantly increased CRC epithelial cell
migration; however, HAPLN1 overexpression substantially reduced
the number of migrated cells (Figure 5E). We then assessed the role
of HAPLN1 in CRC growth using wound healing assays
(Figure 5F). The wounds in the CRC epithelial cells started to
recover 6 h after TGF-b challenge and resolved after 24 h in cells
treated with media control or negative control plasmid (Figure 5G).
However, cells overexpressingHAPLN1 had reduced wound healing
speed, even slower than in control cells without TGF-b challenge,A B
C
FIGURE 2 | Colorectal cancer (CRC) patients have decreased HAPLN1 protein in tumors. (A) Colon tissues were collected from tumors and normal tissue adjacent to the
tumor from CRC patients (n = 59). Tissues were sectioned and stained with HAPLN1 antibody by immunohistochemistry (low magnification scale bar = 200 mm; high
magnification scale bar = 50 mm). (B) The area of HAPLN1 staining in all stages of CRC patients was normalized to the total area of the colon section. (C) The area of HAPLN1
staining in early (stages I and II, n = 36) and severe stages (stages III and IV, n = 18) of CRC patients was normalized to the total area of the colon section. Results are mean ±
SEM. **P < 0.01, ****P < 0.0001 compared with a normal tissue adjacent to the tumors from CPC patients. #P < 0.05 compared with early stage tumour of CPC patients.December 2021 | Volume 11 | Article 754240
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cell growth.
HAPLN1 Regulates Collagen via the TGF-b
Signaling Pathway in CRC
To assess the mechanisms of how HAPLN1 regulates CRC
epithelial cell growth, we transfected these cells with HAPLN1
overexpression plasmid with and without TGF-b for 24 h. TGF-b
significantly reduced the numbers of HAPLN1-positive cells but
increased collagen proteins (COL1A1) in those cells (Figure 6A).
HAPLN1 overexpression restored the numbers of HAPLN1-
positive cells but reduced collagen deposition after TGF-b challenge.
To confirm that HAPLN1 regulates collagen in CRC, we also
collected cell lysates 24 h after HAPLN1 overexpression with or
without 24 h TGF-b challenge. TGF-b reduced the HAPLN1
protein in CRC epithelial cells, and HAPLN1 overexpression
increased the HAPLN1 proteins after TGF-b challenge
compared with control cells (Figures 6B, C and Supplementary
Figure S2A). HAPLN1 overexpressing cells also had reduced
collagen after TGF-b challenge (Figure 6D).Frontiers in Oncology | www.frontiersin.org 7Given that reduced HAPLN1 was associated with increased
collagen in CRC, we investigated the mechanism of how
HAPLN1 regulates collagen in CRC. Previous studies showed
that the TGF-b signaling pathway regulates collagen deposition
(10, 22); thus, we assessed the key downstream proteins (Smad2,
Smad3, Smad4, and COL1A1) in this signaling pathway in
normal colon tissue and tumors from CRC patients. Smad2,
Smad3, Smad4, and COL1A1 proteins were strongly expressed in
tumor tissues from CRC patients compared with normal colon
controls (Figure 6E). We also measured Smad2/3, p-Smad2/3,
and Smad4 proteins in an in-vitromodel of CRC. We found that
Smad2/3, p-Smad2/3 and Smad4 proteins were significantly
increased in CRC epithelial cells after TGF-b challenge, but
were decreased with HAPLN1 over-expression (Figures 6E–I
and Supplementary Figure S2B).
To further understand how HAPLN1 regulates CRC growth, we
assessed E-cadherin protein in our in-vitro model of CRC. E-
cadherin is an important molecule involved in cell adhesion and
tumor development (29). TGF-b challenge increased E-cadherin




FIGURE 3 | TGF-b stimulation reduces HAPLN1 protein in human colorectal cancer (CRC) cells. Human CRC epithelial cells (Caco-2) were challenged with
recombinant TGF-b protein (5 ng/ml), and controls cells received media. (A) HAPLN1 and COL1A1 protein levels were assessed in cell lysates over a time course (6,
12, 24, and 48 h) of TGF-b challenge by immunoblot. Fold change of densitometry of HAPLN1 (B) and COL1A1 (C) was normalized to b-actin. (D) Caco-2 cells
were stained with HAPLN1 and nuclei were stained with DAPI and assessed using immunofluorescence (n = 4, scale bar = 100 mm). p-Smad2/3 (E) and HAPLN1
(F)-positive cells were normalized to total cells to determine the percentage of HAPLN1-positive cells. Results are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001 compared with control cells that received media. ##P < 0.01, ###P < 0.001 compared with TGF-b-challenged cells after 48 h.December 2021 | Volume 11 | Article 754240
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with cells transfected with the negative control plasmid (Figure 6J).DISCUSSION
HAPLN1 is an ECM protein that contributes to cell proliferation,
cell–cell interactions, and tumor development. In this study, we
found that the HAPLN1 gene and proteins are decreased in
tumors from CRC patients compared with colon healthy controls
and normal colon regions of CRC patients. We also show that
decreases in HAPLN1 proteins are associated with increased
COL1A1 protein levels in CRC epithelial cells after TGF-b
challenge and control tumor growth. A potential mechanism is
that HAPLN1 regulates tumor cell proliferation via the TGF-b
(Smad2/3, p-Smad2/3, and Smad4) signaling pathway. HAPLN1
also mediates E-cadherin to regulate tumor cell attachment in
CRC. However, HAPLN1 overexpression restored COL1A1,
TGF-b signaling, and E-cadherin proteins in CRC epithelial cells.
Studies have shown that HAPLN1mRNA is downregulated in
chondrocytes in endoplasmic reticulum stress-induced cartilage
damage (30). HAPLN1 expression is significantly reduced by
interleukin-1 alpha stimulation and further results in decreased
cell proliferation in cartilage injury (31). Previous studies showed
thatHAPLN1mRNA was decreased in brain cells 24 h after TGF-
b-induced brain damage (11). These studies indicate that
HAPLN1 is associated with cell growth, but HAPLN1 levels
vary in different cancers. HAPLN1 gene expression is increased
in lung tissues from patients with pleural mesothelioma comparedFrontiers in Oncology | www.frontiersin.org 8with healthy controls (32), while some other studies showed
HAPLN1 levels decreased during aging, and this is potentially
involved in cancer invasion (6). The decrease in HAPLN1 protein
results in the disruption of the vascular basement membrane and
induces vessel permeability, and this enhances melanoma
metastasis (6). To our knowledge, only one other study has
assessed the HAPLN1 gene in a small cohort (n = 15) of CRC
patients and it was found to be elevated in CRC (12). However,
previous studies indicated that HAPLN1 expression may be
altered during colorectal carcinogenesis (33). In our study, we
observed a decreased gene expression of HAPLN1 in CRC
patients compared with healthy controls and normal tissue
adjacent to the tumor. The decreased in HAPLN1 protein has
also been confirmed in CRC patients by histological analysis in a
larger cohort (n = 59). The HAPLN1 protein is further decreased
in severe CRC patients, indicating a correlation between HAPLN1
and CRC severity. Low levels of HAPLN1 gene in the colon are
associated with a lower survival rate of CRC patients, indicating
that factor downregulation of HAPLN1 may drive CRC
development. We have also shown that epithelial, stromal, and
endothelial cells and myofibroblasts express HAPLN1 gene in the
colon by RNA-sequencing, but only epithelial cells are associated
with tumor formation in CRC.
Abnormal deposition of ECM leads to tissue stiffening and is
associated with the tumor microenvironment in CRC (34).
Collagen is the most abundant component of ECM protein and
increased collagen deposition results in tissue remodeling and
tumor formation (10). We previously showed that collagen




FIGURE 4 | HAPLN1 overexpression increases HAPLN1 but decreases COL1A1 proteins in human colorectal cancer (CRC) epithelial cells. HAPLN1 overexpression
plasmids conjugated with GFP were transfected into human CRC epithelial (Caco-2) cells. (A) GFP-positive cells were assessed over a time course of transfection (0,
6, 12, 24, and 48 h) by immunofluorescence (n = 4, scale bar = 100 mm), and (B) GFP-positive cells were normalized to total cells (per view). (C) HAPLN1 and
COL1A1 proteins were assessed in cell lysates over a time course of HAPLN1 overexpression plasmid transfection (0, 6, 12, 24, and 48 h) by immunoblot. Fold
changes of densitometry of HAPLN1 (D) and COL1A1 (E) were normalized to b-actin. n = 4. Results are mean ± SEM. *P < 0.05, **P < 0.01, ****P < 0.0001
compared with cells 0 h after HAPLN1 overexpression plasmid transfection. #P < 0.05, ####P < 0.0001 compared with cells 48 h after HAPLN1 overexpression
plasmid transfection.December 2021 | Volume 11 | Article 754240
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tumor (26). In this study, we show that COL1A1 protein is
significantly increased in CRC epithelial cells after TGF-b
challenge. We also show that HAPLN1 correlated with collagen
in CRC, indicating that HAPLN1 may regulate collagen in the
tumor microenvironment. Increased collagen deposition in tissues
results in cancer cell proliferation and tumor growth (35).
However, increased collagen is associated with decreased
HAPLN1 in CRC epithelial cells after TGF-b challenge. We also
observed an increase of HAPLN1 protein in CRC epithelial cellsFrontiers in Oncology | www.frontiersin.org 9after 24 h of HAPLN1 overexpression compared with earlier time
points. This leads to a decrease of collagen in the cancer cells,
indicating that HAPLN1 may regulate collagen formation in CRC.
TGF-b is an important cytokine in the regulation of cell
proliferation, differentiation, adhesion, and migration in many cell
types (36). It is a key regulator of ECM products and the
microenvironment in cancers (36). The TGF-b signaling pathway
is involved in cancer development and tumor growth in CRC, and
Smad family members are important downstream molecules in the




FIGURE 5 | HAPLN1 overexpression reduces tumor cell growth in colorectal cancer (CRC). Human CRC epithelial (Caco-2) cells were transfected with HAPLN1
overexpression or negative control plasmid, and vehicle controls received media. Cells were then challenged with human recombinant TGF-b protein. (A) Live cells
were enumerated during the time course of TGF-b challenge (0, 6, 12, and 24 h) using a cell viability assay. (B) Cells were stained with crystal violet after 24 h of
TGF-b challenge and (C) visualized using light microscopy (scale bar = 100 um). (D) Cell migration was assessed by boyden’s chamber assay after 24 hours TGF-b
challenge that Caco-2 cells were stained with crystal violet (scale bar = 100 um) and (E) migrated were counted in at least 5 random fields per well under 20x
magnification lens by an inverted microscope. (F) Cell Scratch assays were performed in wells cultured with Caco-2 cells, and cancer cell invasion and migration
were assessed by wound healing (scale bar = 200 um). (G) Wound area was assessed by measuring wound closure size after 0, 6, 12, and 24 h post-scratch. n =
4. Results are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with control cells. #P < 0.05, ####P < 0.0001 compared with cells
transfected with negative control plasmid.December 2021 | Volume 11 | Article 754240
Wang et al. Loss of HAPLN1 Induces CRCmice are embryonic lethal (38). Smad3 protects against the
development of colorectal tumors, and specifically, knockout of
exon 2 in Smad3 promotes metastasis of large bowel cancer (39).
However, knockout of exon8 in Smad3 results in autoimmunitywith
abnormally activated T cells, and this induces colon inflammation
and adenocarcinomas (40). Smad4 knockout mice are prone to
embryonic lethality due to defects in gastrulation (41). Depletion of
Smad4 from T cells in mice leads to epithelial carcinomas in the gut
(42). We show that TGF-b stimulation increases both Smad2/3 and
p-Smad2/3 proteins in CRC epithelial cells, and this confirmed the
findings of a previous study (43). This demonstrates that the balance
of Smad proteins is critical in tumor formation in CRC. We have
shown that HAPLN1 overexpression in cancer cells restored p-Frontiers in Oncology | www.frontiersin.org 10Smad2/3 to control levels, indicating that HAPLN1 may regulate
the TGF-b signaling pathway.
Changes in the tissue microenvironment contribute to cell–cell
adhesion, and loss of adhesion is a key mechanism of cancer
invasion and progression (44). E-cadherin is a key adhesion
protein that promotes cell–cell adhesion and maintains epithelial
morphology (45). Studies have identified that low levels of E-
cadherin expression are associated with colon cancer invasiveness
(44). The expression of E-cadherin in cancer patients with
metastasis is lower than that in normal tissue adjacent to the
tumor (45). Patients with cancer had decreased E-cadherin
expression and this led to a lower survival time (44). This







FIGURE 6 | HAPLN1 regulates collagen via the TGF-b signaling pathway and E-cadherin to control tumor growth in colorectal cancer (CRC). Human CRC epithelial
(Caco-2) cells were transfected with HAPLN1 overexpression or negative control plasmid, and vehicle controls received media. Cells were then challenged with human
recombinant TGF-b protein. (A) Cells were stained with HAPLN1 and COL1A1 fluorescent antibody after 24 h of TGF-b and assessed by immunofluorescence (scale
bar = 100 mm). (B) HAPLN1 and COL1A1 proteins were assessed in cell lysates by immunoblot. Fold change of densitometry of HAPLN1 (C) and COL1A1 (D) was
normalized to b-actin. (E) Smad2, Smad3, Smad4, and COL1A1 proteins in human colon healthy controls and tumors from CRC patients by immunohistochemistry
in the Pathology Atlas database (scale bar = 200 mm). (F) Smad2/3, Smad4, p-Smad2/3, and E-cadherin proteins were assessed in cell lysates by immunoblot. Fold
change of densitometry of Smad2/3 (G), Smad4 (H), p-Smad2/3 (I), and E-cadherin (J) was normalized to b-actin. n = 4. Results are mean ± SEM. *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001 compared with control cells receiving media. #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001 compared with cells
transfected with negative control plasmid.December 2021 | Volume 11 | Article 754240
Wang et al. Loss of HAPLN1 Induces CRCinvasion, lymph node metastasis, and severity of cancer (46). In
this study, we have shown that TGF-b challenge reduces E-
cadherin protein in CRC cells, and this confirmed previous
observations (47). However, overexpression of HAPLN1 in CRC
cells increased E-cadherin proteins after TGF-b stimulation,
indicating that HAPLN1 regulates E-cadherin and reduces
tumor cell growth.
Taken together, our data show that low levels of HAPLN1
induces collagen deposition in the colon via p-Smad2/3 involved
in the TGF-b signaling pathway. Increased collagen leads to cell
microenvironment changes and tumor cell proliferation,
migration, and invasion in CRC. HAPLN1 overexpression
restored HAPLN1 protein and reduced cancer cell growth
(Figure 7). This provides a new therapeutic approach by
restoring HAPLN1 in CRC patients.DATA AVAILABILITY STATEMENT
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